Exploring the Genetic and Clinical Landscape of Dedifferentiated Endometrioid Carcinoma
Authors:
- Hikaru HaragaHHHikaru Haraga
- Kentaro NakayamaKNKentaro Nakayama
- Sultana RaziaSRSultana Razia
- Masako IshikawaMIMasako Ishikawa
- Hitomi YamashitaHYHitomi Yamashita
- Kosuke KannoKKKosuke Kanno
- Mamiko NagaseMNMamiko Nagase
- Tomoka IshibashiTITomoka Ishibashi
- Hiroshi KatagiriHKHiroshi Katagiri
- Ryuichi ShimomuraRSRyuichi Shimomura
- Yoshiro OtsukiYOYoshiro Otsuki
- Satoru NakayamaSNSatoru Nakayama
Preprint
- 10 March 2025
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Dedifferentiated endometrioid carcinoma (DDEC) is rare, has a poor prognosis, and the genes responsible for dedifferentiation remain unclear. This study aimed to clarify the characteristics of DDEC in Japanese patients and develop treatment strategies. Eighteen DDEC cases were included; their clinicopathological features and prognoses were analyzed and compared to those of other histological subtypes. The samples were divided into well-differentiated and undifferentiated components; immunostaining and whole-exome sequencing (n = 3 cases) were conducted. The incidence of DDEC was 2.0% among endometrial cancers. The 5-year progression-free survival and the 5-year overall survival for DDEC was approximately 40% and 30%, respectively. Immunohistochemistry showed that 66.7% of patients were mismatch repair deficient. The rate of p53 mutations was higher than that reported in previous studies, and patients with p53 mutations in the undifferentiated components had a poor prognosis. Whole-exome sequencing revealed different gene mutations and mutation signatures between well-differentiated and undifferentiated components. New genetic mutations in undifferentiated regions were uncommon in all three cases. One case (case 1) exhibited homologous recombination deficiency, whereas other two showed microsatellite instability-high and hypermutator phenotypes. Genetic analysis suggests that immune checkpoint and poly (ADP-ribose) polymerase inhibitors, and drugs targeting the p53 pathway may be effective against DDEC.Keywords
All Related Versions
This publication has 46 references indexed in Scilit:
- Long-term disease-free survival with chemotherapy and pembrolizumab in a patient with unmeasurable, advanced stage dedifferentiated endometrial carcinomaGynecologic Oncology Reports, 2024
- PARP Inhibitors in Ovarian Cancer: A ReviewTargeted Oncology, 2023
- WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: A biomarker-enriched phase II studyGynecologic Oncology, 2023
- Clinicopathological significance of multiple molecular features in undifferentiated and dedifferentiated endometrial carcinomasPathology, 2021
- SWI/SNF‐deficiency defines highly aggressive undifferentiated endometrial carcinomaThe Journal of Pathology: Clinical Research, 2020
- Dedifferentiated endometrioid adenocarcinoma of the uterus: A case series and review of literatureGynecologic Oncology Reports, 2020
- TCGA Molecular Subgroups in Endometrial Undifferentiated/Dedifferentiated CarcinomaPathology and Oncology Research, 2019
- MMR deficient undifferentiated/dedifferentiated endometrial carcinomas showing significant programmed death ligand-1 expression (sp 142) with potential therapeutic implicationsPathology - Research and Practice, 2019
- Pattern of SMARCB1 (INI1) and SMARCA4 (BRG1) in poorly differentiated endometrioid adenocarcinoma of the uterus: analysis of a series with emphasis on a novel SMARCA4-deficient dedifferentiated rhabdoid variantAnnals of Diagnostic Pathology, 2015
- Hereditary Leiomyomatosis and Renal Cell Cancer: A Syndrome Associated With an Aggressive Form of Inherited Renal CancerJournal of Urology, 2007